文献速递胸部肿瘤放疗放疗物理与技术

TROG 21.08 VITaL试验研究方案:通气成像改善肺癌放疗患者生活质量的随机对照试验

Study protocol for the TROG 21.08 VITaL trial: a randomized controlled trial investigating ventilation imaging to improve the quality of life for patients with lung cancer treated with radiation therapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-10-08

VITaL是一项双盲随机对照试验,计划入组165例III期非小细胞肺癌患者,比较基于CT通气成像(CTVI)的健康肺保护性放疗与标准放疗。主要假设是健康肺保护性放疗患者的生活质量优于标准放疗,采用FACT-L问卷评估,随访3年。

要点

  • CTVI由呼气与吸气屏气CT配对生成,用于指导优先避开高通气区域。
  • 每例患者均制定健康肺保护计划和标准计划,按1:1随机分配治疗。
  • 主要终点为生活质量(FACT-L问卷),随访持续3年。

核心结论

  • 该试验将确定基于CTVI的健康肺保护性放疗能否改善III期NSCLC患者生活质量、减少肺毒性并提高接受根治性免疫治疗的资格。

研究设计与样本

  • 双盲随机对照试验(TROG 21.08 VITaL),计划入组165例接受放疗的III期非小细胞肺癌患者。
  • 每例患者生成健康肺保护计划和标准计划,按1:1比例随机分配用于实际治疗。
  • CTVI由呼气与吸气屏气CT扫描配对生成,随访持续3年。

主要发现

  • 原文未报告试验结果,仅为研究方案。

关键数值与推荐

  • 主要假设:健康肺保护性放疗患者的生活质量优于标准放疗患者。
  • 生活质量采用癌症治疗功能评估-肺问卷(FACT-L)在治疗前后评估。
  • 次要假设包括健康肺保护组治疗副作用更少、肺功能更好、更可能接受并完成辅助免疫治疗,且具有成本效益。

临床怎么用

  • 放疗计划中利用CTVI识别高与低功能区,将剂量引导至低通气区域以保护健康肺组织。

局限性

  • 原文为研究方案,尚无结果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation therapy (RT) is indicated for 77% of patients with lung cancer. Over 20% of patients are affected by radiation-induced lung injury. Computed tomography ventilation imaging (CTVI) estimates high and low functioning lung regions. During RT planning, CTVI can guide preferential avoidance of higher ventilated regions by redirecting dose to less well ventilated regions, sparing healthy lung tissue. The double-masked randomized Trans-Tasman Radiation Oncology Group (TROG) 21.08 VITaL trial will investigate if sparing healthy lung can improve the quality of life (QoL) for patients with stage 3 non-small cell lung cancer (NSCLC) treated with RT. METHODS: 165 patients will be recruited to test the hypothesis that patients receiving healthy lung-sparing RT have better QoL than patients receiving standard RT. CTVI will be generated from exhale and inhale breath-hold CT scan pairs. A healthy lung-sparing plan and a standard treatment plan will be created for each patient and randomly assigned in a 1:1 ratio for the patient's treatment. QoL will be assessed with the Functional Assessment of Cancer Therapy-Lung questionnaire before and after treatment. Secondary hypotheses include that patients in the healthy lung-sparing arm will have fewer treatment side effects, better lung function, be more likely to receive and complete adjuvant immunotherapy, and healthy lung-sparing treatment will be cost-effective. Patient follow-up will continue for three years. DISCUSSION: This prospective randomized trial will determine whether the incorporation of healthy lung-sparing RT based on CTVI improves QoL, reduces pulmonary toxicity, and increases eligibility to receive curative immunotherapy for patients with stage 3 NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov (NCT06127654).

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vino D SK, Gebski V, Senthi S, et al. Study protocol for the TROG 21.08 VITaL trial: a randomized controlled trial investigating ventilation imaging to improve the quality of life for patients with lung cancer treated with radiation therapy. Clin Transl Radiat Oncol. 2026. PMID: 42910049. doi:10.1016/j.ctro.2026.101312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。